DOCSLIB.ORG

Still Don't Believe in a Biotech Bubble? Check out Axovant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Still Don't Believe in a Biotech Bubble? Check out Axovant June 12, 2015 Still don’t believe in a biotech bubble? Check out Axovant Jacob Plieth Anyone taking a cursory glance at Axovant could be excused for assuming that the new Nasdaq entrant’s sole pipeline asset, for Alzheimer’s disease, was a first-in-class project guaranteed to generate blockbuster sales. In reality Axovant’s RVT-101 is nothing of the sort, having to contend with advanced competition from the likes of Lundbeck and Pfizer, and the fact that many similar projects have been abandoned (see table below). RVT- 101 was itself ditched by GlaxoSmithKline, but this and numerous other red flags have not stopped Axovant from completing one of the most successful floats of recent times. The company’s upsized IPO on Nasdaq yesterday raised $315m, putting it ahead of Juno Therapeutics and just behind Circassia’s record-breaking £200m ($332m) float in 2014. At the close of play yesterday Axovant shares were up 99%, valuing the eight-month-old company at $2.8bn. Bubble mania Given the numerous alarm bells around Axovant it is hard to put this level of exuberance down to much more than biotech bubble mania. From a purely financial perspective it is not clear why investors would back a company staking all on a project that Glaxo had been willing to abandon for just $5m, and which is still a majority-owned subsidiary of a separate holding company, Roivant Sciences. After the float Roivant holds an 81% stake in Axovant. Axovant’s chief executive, the 29-year-old Vivek Ramaswamy, also heads up Roivant and chairs Tekmira Pharmaceuticals, the RNAi business in which Roivant has a 30% equity stake. These issues have been spelled out in detail by Adam Feuerstein at Thestreet.com so there is little point going over them here. However, there are also scientific questions about RVT-101 and its place in the high-risk Alzheimer’s disease market. The compound works by inhibiting the 5-HT6 receptor, which is expressed in brain regions involved in cognition and might play a role in modulating the activity of neurotransmitter systems. Under the code SB742457, RVT-101 completed four phase II studies in 1,840 patients, but reported data are at best mixed. One study did show an effect on the Adas-Cog scale but not on the CDR-SB measure, while another failed to hit either Adas-Cog or Cibic+. A third showed a borderline effect on Cibic+ but not Adas-Cog. Then there is the threat of more advanced competitors. Lundbeck’s idalopirdine, for instance, hit an Adas-Cog endpoint in hard-to-treat moderate disease, and was picked up by Otsuka for $150m up front; it is now in a huge pivotal programme in 4,260 patients that could start reading out this year (Lundbeck’s non-amyloid Alzheimer’s move could embolden others, October 11, 2013). A selection of 5-HT6 antagonists Project Company Status Lu AE58054 (idalopirdine) Lundbeck/Otsuka Phase III PF-05212377 Pfizer Phase II RVT-101/SB742457 Axovant/Roivant Phase II AVN-101 Avineuro/AllaChem Phase II ABT-354 AbbVie Phase I SUVN-502 Suven Life Sciences Phase I AVN-322 Avineuro/AllaChem Phase I Abandoned - phase SAM-531 (cerlapirdine) Pfizer II SYN-114 Roche Abandoned - phase I SYN-120 Roche Abandoned - phase I SB 271046 GlaxoSmithKline Abandoned - phase I BVT74316 Swedish Orphan Biovitrum Abandoned - phase I SYN-114 Biotie Therapies Abandoned - phase I Source: EvaluatePharma. Avineuro has several 5-HT6 projects, the most advanced of which is AVN-101, while Pfizer’s PF-05212377 is in a 342-patient phase II trial that ends next year. Then there are the failures, including clinical assets from Roche, Pfizer and Glaxo, though it could be argued that the latter two represent duds that had led to development of the current projects. True, no matter how advanced the competition, first in class is nowhere near as important as best in class, but based on Glaxo’s questionable data this assumption would be a stretch. Instead, Axovant looks like biotech float in a similar league to Sage Therapeutics – worth $2.5bn on the back of a single-arm, four-patient trial – or Blueprint Medicines, now at $857m despite never yet having put any of its kinase inhibitors into a single patient. Biotech bulls will insist that this time things really are different, but the unusual case of Axovant suggests otherwise. To contact the writer of this story email Jacob Plieth in London at [email protected] or follow @JacobPlieth on Twitter More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Pfizer Inc. – Product Pipeline Review – 2014
    Pfizer Inc. – Product Pipeline Review – 2014 Reference Code: GMDHC06172CDB Publication Date: SEP 2014 Pfizer Inc. – Product Pipeline Review – 2014 GMDHC06172CDB / Published SEP 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Pfizer Inc. – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 22 List of Figures ...................................................................................................................................................................... 22 Pfizer Inc. Snapshot ................................................................................................................................................................. 23 Pfizer Inc. Overview ............................................................................................................................................................. 23 Key Information ................................................................................................................................................................... 23 Key Facts ...........................................................................................................................................................................
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    1521-0081/68/1/168–241$25.00 http://dx.doi.org/10.1124/pr.115.011411 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:168–241, January 2016 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: MARKKU KOULU Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions Janne T. Backman, Anne M. Filppula, Mikko Niemi, and Pertti J. Neuvonen Department of Clinical Pharmacology, University of Helsinki (J.T.B., A.M.F., M.N., P.J.N.), and Helsinki University Hospital, Helsinki, Finland (J.T.B., M.N., P.J.N.) Abstract ...................................................................................169 I. Introduction . ..............................................................................169 II. Basic Characteristics of Cytochrome P450 2C8 . ..........................................170 A. Genomic Organization and Transcriptional Regulation . ...............................170 B. Protein Structure ......................................................................171 C. Expression .............................................................................172 III. Substrates of Cytochrome P450 2C8. ......................................................173 A. Drugs..................................................................................173 1. Anticancer Agents...................................................................173 Downloaded from 2. Antidiabetic Agents. ................................................................183 3. Antimalarial Agents.................................................................183
    [Show full text]
  • 101 MULEBUHRMANNUS009969726B2 (12 ) United States Patent (10 ) Patent No
    101 MULEBUHRMANNUS009969726B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 969 , 726 B2 Cosford et al. (45 ) Date of Patent: May 15 , 2018 ( 54 ) METABOTROPIC GLUTAMATE RECEPTOR C07D 231/ 12 ( 2006 .01 ) NEGATIVE ALLOSTERIC MODULATORS C07D 409 / 14 ( 2006 . 01 ) (NAMS ) AND USES THEREOF C07D 413 /04 ( 2006 .01 ) C07D 401/ 14 (2006 .01 ) @( 71 ) Applicant: Sanford - Burnham Medical Research (Continued ) Institute , La Jolla , CA (US ) ( 52 ) U . S . CI. @( 72 ) Inventors : Nicholas David Peter Cosford , La CPC . .. COZD 417 / 14 (2013 . 01 ) ; A61K 31/ 505 Jolla , CA (US ) ; Dhanya (2013 .01 ) ; A61K 31/ 506 ( 2013. 01 ) ; C07D Raveendra - Panickar , La Jolla , CA 231/ 12 ( 2013 .01 ) ; C07D 233 /64 (2013 .01 ) ; (US ) ; Douglas J . Sheffler , La Jolla , CA C07D 239 /26 ( 2013 . 01 ) ; CO7D 243 / 12 (US ) (2013 .01 ) ; C07D 249 / 08 ( 2013 .01 ) ; C07D 261/ 08 ( 2013 .01 ) ; C07D 263 /32 ( 2013 . 01 ) ; @( 73 ) Assignee : SANFORD - BURNHAM MEDICAL C07D 271 /06 ( 2013 .01 ) ; C07D 275 / 02 RESEARCH INSTITUTE , La Jolla , ( 2013 . 01 ) ; C07D 277 / 26 ( 2013 .01 ) ; C07D CA (US ) 277 /30 ( 2013. 01 ) ; CO7D 285 /08 ( 2013 .01 ) ; C07D 307/ 38 ( 2013 .01 ) ; C07D 333 /24 ( * ) Notice : Subject to any disclaimer, the term of this ( 2013 .01 ) ; C07D 401/ 04 (2013 .01 ) ; C07D patent is extended or adjusted under 35 401/ 10 ( 2013 .01 ) ; C07D 401/ 14 ( 2013 .01 ) ; U . S . C . 154 (b ) by 0 days . days . CO7D 403 / 12 (2013 .01 ) ; C07D 405 /04 @( 21 ) Appl. No .: 15 /315 , 363 ( 2013 .01 ) ; C07D 405 / 10 (2013 .01 ) ; C07D 409 /02 (2013 . 01 ) ; C07D 409 / 04 ( 2013 .01 ) ; ( 22 ) PCT Filed : Jun .
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Onadotropin-Releasing Hormone Receptor CLAVULANIC ACID
    ARGININE DAPAGLIFLOZIN ORVEPITANT ORLISTAT Nitric oxideNitric-oxide synthase- synthase- inducible brain Sodium/glucose cotransporter 1 Substance-P receptor Gastric triacylglycerolSodium/glucose lipase cotransporter 2 Platelet activating factor receptor Cystic fibrosis transmembrane conductance regulator Pancreatic lipase-related protein 2 Pancreatic triacylglycerol lipase IVACAFTOR LUMACAFTORDENUFOSOL TETRASODIUM Pyrimidinergic receptor P2Y6 GABA receptorPENTOBARBITAL beta-3 subunit TEZOSENTAN Geranylgeranyl transferase type I Endothelin receptor ET-A TIPIFARNIB Leukocyte commonCholecystokinin antigen B receptor PurinergicPyrimidinergic receptor receptor P2Y2 P2Y4 TALNETANT DARUSENTANIRBESARTAN ETOPOSIDECaspase-3HYDROGEN PEROXIDE TETRACYCLINE Transcription factor AP-1 Glutamate racemase REPARIXIN Serotonin (5-HT) receptor Interleukin-8 receptor A ONDANSETRON AZITHROMYCIN Vasopressin V1 receptor Cyclin-dependent kinase 1/cyclin B Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Smoothened homologNAVITOCLAX SILMITASERTIB VASOPRESSIN AMSACRINEDNA topoisomerase II IVERMECTINalpha EPIRUBICINAMILORIDE HYDROCHLORIDE HYDROCHLORIDE VISMODEGIBBcl2-antagonist of cell death (BAD) MIDOSTAURIN CANNABIDIOL ICLAPRIM CLARITHROMYCIN IRINOTECAN HYDROCHLORIDE HYDRATE VINCRISTINELEUCOVORIN SULFATE CALCIUM DNA topoisomerase II TELITHROMYCINCARBOPLATIN CEFDITOREN PIVOXIL BENFOTIAMINETERIPARATIDE RIFAMYCIN RIFAXIMIN GLUTATHIONE BENZALKONIUM CHLORIDE Mammalian target of Rapamycin (mTORC1) CLINDAMYCIN BETAMETHASONEDONEPEZILMEPARTRICIN HYDROCHLORIDE RUTIN c-Jun
    [Show full text]
  • Fragment-Based Approaches in GPCR-Targeted Drug Discovery Thesis
    Fragment-based approaches in GPCR-targeted drug discovery Thesis Ádám Andor Kelemen PhD candidate György Miklós Keserű DSc, FRSC supervisor Medicinal Chemistry Research Group Research Centre for Natural Sciences Hungarian Academy of Sciences Budapest 2018 Table of contents Table of contents ................................................................................................ 2 List of abbreviations .......................................................................................... 7 Acknowledgements ......................................................................................... 10 Chapter 1 – Introduction ................................................................................ 11 1.1. Fragment-based drug discovery ........................................................ 11 1.1.1. Concept of Fragment-based drug discovery ............................. 11 1.1.2. Strategies and examples ............................................................... 12 1.1.2.1. Fragment-based drug design workflow .................................. 12 1.1.2.2. Fragment optimization strategies............................................. 13 1.2. G-Protein Coupled Receptors ............................................................. 14 1.2.1. Signalization and classification ................................................... 14 1.2.2. X-Ray crystal structures of aminergic GPCR’s .......................... 19 1.3. Medicinal Chemistry of Serotonin (5-HT) receptor ligands ........... 21 1.3.1. Serotonin Receptor Subtype 6 (5-HT6R)64
    [Show full text]
  • Synthèse De Ligands Iodés Et Fluorés En Série Indazole: Application En
    THÈSE Pour obtenir le diplôme de doctorat Spécialité SCIENCES DE LA VIE ET DE LA SANTE Préparée au sein de l'Université de Caen Normandie Synthèse de ligands iοdés et fluοrés en série indazοle : applicatiοn en imagerie des récepteurs 5-ΗΤ4 centraux Présentée et soutenue par Reynald MANGEANT Thèse soutenue publiquement le 18/12/2020 devant le jury composé de Professeur des universités, Université de Mme MURIEL DUFLOS Rapporteur du jury Nantes Professeur des universités, Université M. FRANCK SUZENET Rapporteur du jury d'Orléans Maître de conférences HDR, Université M. THOMAS CAILLY Membre du jury Caen Normandie M. BERTRAND KUNHAST Docteur, CEA Saclay Membre du jury Professeur des universités, Université Mme VALERIE COLLOT Directeur de thèse Caen Normandie Thèse dirigée par VALERIE COLLOT, Centre d'études et de recherches sur le médicament de normandie (Caen) A Madame Valérie Collot, Professeur des Universités de Caen A Madame Muriel Duflos, Professeur des Universités de Nantes A Monsieur Franck Suzenet, Professeur des Universités d’Orléans A Monsieur Thomas Cailly, Maître de conférences des Universités de Caen A Monsieur Bertrand Kuhnast, Docteur au Commissariat à l’Energie Atomique et aux énergies alternatives Qui me font l’honneur de lire ce manuscrit Et de juger mon travail, En témoignage de ma profonde reconnaissance 1 1 2 2 « Dans la vie, rien n’est à craindre, tout est à comprendre » Marie Curie (1867-1934) – Physicienne 3 3 4 4 Remerciements Je souhaiterais en premier lieu remercier ma directrice de thèse, le Pr. Valérie COLLOT. Depuis 3 ans, nous travaillons et collaborons ensemble sur notre « indazole project » et je souhaiterais te dire à quel point je te suis reconnaissant pour tout le temps que tu as consacré à mon égard, pour ta disponibilité et ta patience ainsi que pour tous les bons moments qu’on a partagés ensemble dans notre « indazole team ».
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 25, No. 4, 2011 WHO Drug Information Contents Regulatory Focus Romiplostim: acute myelogenous Seven years of EU pharmaceutical leukaemia 366 regulation in Malta 343 International Pharmaceutical Federation: pharmacovigilance International Harmonization seminar in India 366 Integration and application of equi- valent regulatory assessments Regulatory Action and News from other countries 354 Recommended composition of influenza vaccines: 2012 Safety and Efficacy Issues southern hemisphere 369 Asenapine maleate: serious Aprotinin: resumed marketing 369 allergic reactions 358 First ever PUMA for buccal Lenalidomide: positive benefit-risk midazolam 369 balance 358 Fidaxomicin approved for Citalopram: dose-related cardiac Clostridium difficile infection 370 risk 358 Dronedarone: restricted use 370 Terpenic derivatives: new contra- Voclosporin: withdrawal of market- indications 359 ing authorization application 370 Gonadotropin-releasing hormone: Lacosamide syrup: change in cardiovascular risk 359 formulation 371 Uromitexan: infant fatal gasping New database of European syndrome 359 experts 371 Dasatinib: pulmonary arterial hypertension 360 Consultation Documents Drospirenone: increased risk of The International Pharmacopoeia blood clots 360 Bulk density and tapped density Ondansetron: QT prolongation 361 of powders 374 TNFα blockers: Legionella and Tablet friability 378 Listeria 362 Test for bacterial endotoxins 380 Neonates exposed to antipsychotic Test for sterility 391 drugs: withdrawal symptoms 363 Chewable albendazole tablets 400 Strontium ranelate: cardiovascular Artenimol 403 and cutaneous toxicity 364 Medroxyprogesterone injection 406 Bevacizumab: ovarian failure 364 Ritonavir tablets 409 Gadolinium: nephrogenic systemic fibrosis 365 International Nonproprietary Orlistat-containing medicines Names under review 365 Proposed List No. 106 413 341 WHO Drug Information Vol. 25, No. 4, 2011 WHO Drug Information & digital library are available online at: http://www.who.int/druginformation 342 WHO Drug Information Vol.
    [Show full text]
  • Disposition and Metabolic Profiling of [14C] Cerlapirdine Utilizing
    DMD Fast Forward. Published on September 12, 2014 as DOI: 10.1124/dmd.114.059675 This article has not been copyedited and formatted. The final version may differ from this version. DMD #59675 Disposition and Metabolic Profiling of [14C]Cerlapirdine Utilizing Accelerator Mass Spectrometry (AMS) Susanna Tse, Louis Leung, Sangeeta Raje, Mark Seymour, Yoko Shishikura, R. Scott Obach Pfizer Inc., Groton, CT (S.T., L.L., R.S.O.) and Collegeville PA (S.R.); Xceleron Inc., Germantown, MD (M.S., Y.S.) Downloaded from dmd.aspetjournals.org at ASPET Journals on September 26, 2021 1 DMD Fast Forward. Published on September 12, 2014 as DOI: 10.1124/dmd.114.059675 This article has not been copyedited and formatted. The final version may differ from this version. DMD #59675 Running Title: Metabolism of Cerlapirdine in Humans Address Correspondence to: Susanna Tse Pharmacokinetics, Dynamics and Metabolism-New Chemical Entities Pfizer Inc. Eastern Point Road Downloaded from Groton, CT 06340, USA. Telephone number: 1-860-715-5942 dmd.aspetjournals.org Fax number: 1-860-715-6427 Email: [email protected] at ASPET Journals on September 26, 2021 Text Pages (including references): 36 Tables: 3 Figures: 9 References: 44 Words in: Abstract: 242 Introduction: 617 Discussion: 1198 2 DMD Fast Forward. Published on September 12, 2014 as DOI: 10.1124/dmd.114.059675 This article has not been copyedited and formatted. The final version may differ from this version. DMD #59675 Abbreviations used: PF-05212365: N,N-dimethyl-3-{[3-(naphthalen-1-ylsulfonyl)-2H- indazol-5-yl]oxy}propan-1-amine;
    [Show full text]